PLSE vs ANAB vs RCUS vs INVA vs FOLD

For growth investors, AnaptysBio, Inc.

(ANAB) is the stronger pick with 157. 0% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate Pulse Biosciences, Inc. (PLSE) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Innoviva, Inc.

is actually cheaper at 7. 3x.

Over the past 5 years, AnaptysBio, Inc.

(ANAB) delivered a total return of +304. 3%, compared to -12. 1% for Arcus Biosciences, Inc. (RCUS). Over 10 years, the gap is even starker: ANAB returned +511. 9% versus RCUS's +49. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 11β versus Pulse Biosciences, Inc. 's 1. 91β — meaning PLSE is approximately 1583% more volatile than INVA relative to the S&P 500. On balance sheet safety, Pulse Biosciences, Inc. (PLSE) carries a lower debt/equity ratio of 9% versus 176% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AnaptysBio, Inc.

(ANAB) is pulling ahead at 157. 0% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -17. 4% for Pulse Biosciences, Inc.. Over a 3-year CAGR, ANAB leads at 183. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -207. 9% for Pulse Biosciences, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -219. 8% for PLSE. At the gross margin level — before operating expenses — ANAB leads at 99. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Innoviva, Inc.

(INVA) trades at 7. 3x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 33. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INVA: 74. 7% to $40. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 11)). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INVA: +95. 6%, RCUS: +49. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PLSE is a small-cap quality compounder stock; ANAB is a small-cap high-growth stock; RCUS is a small-cap quality compounder stock; INVA is a small-cap high-growth stock; FOLD is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.